a Calculated using the EPA's Benchmark Dose Software (BMDS 3.1); b Calculated using the web-based interface: Bayesian BMD (BBMD) estimation (https://benchmarkdose.org/) (Shao and Shapiro 2018); c The values represent the estimated EC10 or BMD with its lower-and upper confidence limit.
Dose-response data sets
In this study, we collected dose-response data sets from human epidemiological studies, animal in vivo toxicity studies and ToxCast in vitro assays for a comprehensive dose-response evaluation.
The datasets consisted of 34 studies and 7 endpoints: increased serum cholesterol, increased liver weight, PPAR activation, neurotoxicity, immunotoxicity, endocrine disruption and cellular responses (including cytotoxicity, mitochondria, oxidative stress, DNA binding and cell cycle).
The datasets are listed in Table 1 and Table 2 of the manuscript.
Human epidemiological studies

Mode of action (MOA) considerations for human studies
According to the comprehensive literature review by EFSA (EFSA, 2018) , numerous human studies have investigated potential association between PFOS or PFOA exposure and serum cholesterol levels. Most of them show significant positive associations between PFOS and/or PFOA and total cholesterol (Eriksen et al., 2013; Fitz-Simon et al., 2013; Frisbee et al., 2010; Geiger et al., 2014; Skuladottir et al., 2015; Starling et al., 2014; Yu et al., 2005) . For PFOS, only one of these studies shows clear null results (Lin et al., 2011) . Based on these human studies, EFSA concludes that it's likely there is a causal association between PFOS and increase of serum cholesterol. However, the exact mechanism of how PFOS increases human serum cholesterol levels remains unclear. Based on the latest EPA report (U.S. EPA, 2016), the possible MOA is that high-density lipoproteins (HDLs) bind cholesterol from other serum lipoprotein complexes and transport it to the liver for degradation and conversion to bile salts (Montgomery et al. 1990) . Competition between PFOS and bile salts for biliary transport could result in impeded removal of HDL lipids from serum and increase both HDL cholesterol and total cholesterol. In addition, HDLs have the highest ratio of proteins to lipids (50:50) among the serum lipoprotein complexes (Montgomery et al. 1990 ). Binding of PFOS to HDL protein could impede the HDL interaction with liver tissue receptors resulting in increased serum levels of HDL.
However, the inverse association between cholesterol and serum PFOS concentration was observed in rodents (Elcombe et al., 2012; Minata et al., 2010; Wang et al., 2013) . The differences of susceptibility between primates and rodents on the activation of PPARa might be one of reasons to account for this species-specific effect. Additional studies are needed to elucidate the mechanisms of how PFOS changes serum cholesterol concentrations in different species.
Selected critical human epidemiological studies
Numerous epidemiologic studies have evaluated the potential association between serum lipid status and plasma PFOS concentrations, and they have reported a significant association between PFOS exposure and the increase in total serum cholesterol level in the general population (Table   1 ). Four cohort studies were included in our dose-response analyses with different human populations, including the U.S. NHANES (National Health and Nutrition Examination Survey) volunteers (Nelson et al., 2010) , the U.S. C8 Health Project participants ), Danish population (Eriksen et al., 2013) , and Inuit population (Château-Degat et al., 2010) • U.S. population: examined the levels of serum PFOS, PFOA, and lipids among 46,294 residents, ≥18 years old, participating in the C8 Health Project. The mean serum PFOS levels were determined to be 0.022 µg/mL with a range of 0.00025 -0.7592 µg/mL. The lipid outcomes including total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were determined to investigate the potential association between serum PFOA/PFOS levels and the lipid endpoints. In the NHANES study, Nelson Approximately 860 participants (20-80 years old) were included in the analyses with the mean PFOS serum concentration of 0.025 µg/mL (range: 0.0014-0.392 µg/mL). A significant positive association was identified between total serum cholesterol and serum PFOS concentrations.
• Danish population: In the Danish cohort (n = 753; 663 males and 90 females), Eriksen et al. (Eriksen et al., 2013) examined the association between plasma PFOS levels and total cholesterol levels in a middle-aged (50-65 years) Danish population. The mean plasma PFOS level was 0.0361 µg/mL. A significant positive association was found between serum PFOS levels and total serum cholesterol levels. In addition, a 4.6 mg/dL (95% CI: 0.8-8.5) higher concentration of total cholesterol was found per interquartile range of plasma PFOS level.
• Inuit population: In the Inuit population (n = 723), a cross-sectional epidemiological study was conducted to evaluate the effect of PFOS exposure on blood lipids. The mean PFOS concentration was 18.6 ng/mL (geometric mean) with 95% CI of 17.8 -19.5 ng/mL. A positive trend was identified between total cholesterol and PFOS exposure, but it was no longer statistically significant after an adjustment for confounders.
Animal in vivo toxicity studies
Mode of action (MOA) considerations for animal studies
Many experimental studies have shown that the liver is the primary target organ for PFOS in animals (Fai Tse et al., 2016; Han et al., 2018; Wan et al., 2016) . However, the MOA responsible for the increase of liver weight due to PFOS exposure is not well understood. Based on the EFSA report (EFSA, 2018), one of possible mechanisms of PFOS-induced liver toxicity appears to be the activation of xenobiotic-sensing nuclear receptors such as PPARα, constitutive androstane receptor (CAR), and pregnane X receptor (PXR) in the liver. The association of the incidence of liver tumor and hepatomegaly with the activation of xenosensor nuclear receptors in rodents has been well established (Lake, 2009) . Specifically, the increase in liver weight can result from increased peroxisomal mass and expansion of the smooth endoplasmic reticulum by the activation of PPARα (Vanden Heuvel et al., 2006) . The activation of CAR and PXR can also increase liver weight through the production of cytochromes with a consequent increase in cytochromal proteins (Elcombe et al., 2014) . In addition, activation of PPARα, CAR, or PXR in rodents may trigger replicative DNA synthesis, resulting in proliferation of hepatocytes, and may decrease apoptosis of hepatocytes, potentially leading to clonal expansion of preneoplastic foci and, ultimately, liver carcinogenesis (Lake, 2018; Shizu et al., 2013) . However, the mechanism for the observed liver toxicity in primates might be different from rodents because recent studies have shown relative less susceptibility of primates compared with rodents to peroxisome proliferation (Gonzalez and Shah, 2008) . There might be other pathways/mechanisms by which PFOS can interfere with lipid metabolism in the liver in primates. Recently, Xu et al. (Xu et al., 2017) reported that the ERβ knockout mice did not have the adverse effects (hepatocyte vacuolization, hydropic degeneration, changes in levels of cholesterol and bile acids) that were observed in PFOS-exposed wild-type mice, suggesting the PFOS-induced liver toxicity may also involve the ERβ pathway.
Selected critical animal studies
Six animal studies in different species including the mouse, rat and monkey were included in our dose-response analyses (Table 1) . These studies consistently show that PFOS exposure is significantly associated with increased absolute/relative liver weight. These studies are described in detail below:
• Mouse: Two mouse studies were included in our analyses. Dong and his co-workers conducted two mouse studies for PFOS exposure published in 2009 (Dong et al., 2009) and 2011 (Dong et al., 2011) , respectively. Although the studies aimed to examine PFOSinduced immunotoxicity, the liver weight was also measured and found to be increased significantly. In the first study (Dong et al., 2009) , adult male C57BL/6 mice were exposed to PFOS daily via oral gavage for 60 days at the dose of 0, 0.5, 5, 25, 50, or 125 mg/kg/day.
Their results showed that liver weight was significantly increased at the groups of ≥5 mg/kg/day in a dose-dependent manner. In the second study (Dong et al., 2011) , adult male C57BL/6 mice were exposed to PFOS daily via oral gavage for 60 days at the dose level of 0, 0.5, 5, 25, or 50 mg/kg/day. The results showed that several immune biomarkers were altered in a dose-dependent manner at ≥5 mg/kg/day dose groups, and the liver weight was also significantly increased at doses as low as 25 mg/kg/day.
• Rat: Three rat studies were included in our analyses. In the first study, Seacat and his coworkers (Seacat et al., 2003) conducted a 14-week (98-day) study in Sprague-Dawley (SD) rats. Rats were administered PFOS via the diet at concentrations of 0, 0.5, 2, 5, and 20 ppm (i.e., 0, 0.03, 0.13, 0.34, and 1.33 mg/kg in males and 0, 0.04, 0.15, 0.40, and 1.56 mg/kg in females) for 14 weeks (98 days). A thorough necropsy was performed at the end of treatment, and liver samples were collected. Absolute and relative (to body weight) liver weights were increased significantly in the males and males/females, respectively. In the second study , Sprague-Dawley rats were treated with PFOS at 0, 0.14, 1.33, 3.21 or 6.34 mg/kg/day for 28 days, and the changes in clinical chemistry, hematology, histopathology, tissue residues and other effects were assessed. Tissue residue results showed a dose-dependent increase in most groups and mostly observed in liver. In the third study (Lefebvre et al., 2008) , Sprague-Dawley rats were exposed to PFOS via dietary exposure for 28 days at the doses ranging from 0.14 to 7.58 mg/kg/day and compared with those receiving control diet. The results showed that the body weight was significantly reduced in male and female rats exposed to 50 and 100 mg PFOS/kg diet. Moreover, the liver weight was significantly increased in females exposed to 2 mg/kg diet and in males exposed to 20 mg/kg diet.
• Monkey: Only one monkey study was included in our study. Seacat et al. (2002) administered 0, 0.03, 0.15, or 0.75 mg/kg/day of PFOS orally in a capsule by intragastric intubation to cynomolgus monkeys (n=6). PFOS levels were determined in serum and liver tissue. Except for the group of 0.03 mg/kg/day, animals in other groups were exposed to PFOS for 26 weeks (182 days). Liver samples were obtained for hepatic peroxisome proliferation determination and immunohistochemistry. Mean absolute and relative (to body weight) liver weights were increased significantly in the 0.75 mg/kg/day dose group for both males and females.
ToxCast in vitro assays
Mode of action (MOA) considerations for in vitro studies
The Toxicity Forecaster (ToxCast) database includes a large amount of high throughput screening datasets of in vitro and in vivo assays on over 9,000 chemicals. The 24 PFOS-activated in vitro assays which may link to PFOS-induced adverse outcomes were selected. The use of these in vitro assays was based on the hypothesis that these molecular initiating events (i.e., receptor activation) triggered by PFOS exposure might link cellular perturbations to adverse outcomes. For example, PPAR and ER activation support the MOA of PFOS-induced liver toxicity of PFOS observed in animal studies described previously (Chou et al., 2017; Das et al., 2017; Palmisano et al., 2017) .
In addition, the cellular responses, such as cytotoxicity, oxidative stress, DNA binding and cell cycle effects have been reported to link to the PFOS-induced toxicity (Pierozan and Karlsson, 2018) . However, more specific mechanisms of each of these in vitro endpoints remain to be investigated.
Selected critical ToxCast in vitro assays
Twenty-four ToxCast assays were included in our study as shown in Table 2 . These assays were designed to evaluate the effects of chemicals (e.g., PFOS) on the activities of human enzymes and transcription factors, including cell-free enzymatic and ligand-binding high-throughput screening assays (labeled with "NVS") , cell-based nuclear receptors and transcription factor response element (labeled with "ATG") (Martin et al., 2010) , cell-based high-content imaging (labeled with "APR") (Shah et al., 2016) and cell-based protein expression (labeled with "BSK") (Houck et al., 2009 ). Based on the U.S. EPA report (U.S. EPA, 2016), these in vitro doseresponse data sets were categorized into six groups by the molecular targets, including PPAR activation, neurotoxicity (in vitro), immunotoxicity, endocrine disruptors, and cellular responses (including cytotoxicity, mitochondria, oxidative stress, DNA binding and cell cycle effects). These molecular targets are discussed in detail below:
• PPAR activation: Several studies have reported that PFOS can activate the PPAR pathway (Palmer et al., 1998; Shipley et al., 2004; Takacs and Abbott, 2007) . In the ToxCast program, PFOS was found to induce DNA expressions of PPAR alpha (PPARα), peroxisome proliferator hormone response elements (PPRE), PPAR gamma (PPARγ), and to antagonize PPARγ receptor (Wambaugh et al., 2013) . We included PPARα, PPRE and PPARγ assays in the present dose-response analysis.
• Neurotoxicity: Five different neurological receptor families with seven different receptor types in ToxCast cell-based assays were activated by PFOS, including 5-hydroxytryptamine receptor (5HT) 5a, 6, and 7, adenosine A2a receptor (ADORA2), adrenoceptor alpha 2C (ADRA2C), and beta 1 (ADRB1) (U.S. EPA, 2016). These receptors are involved in the effects of neurotoxicity and were included in our study.
• Immunotoxicity: In the ToxCast program, PFOS was found to be able to induce the expression of a variety of genes associated with immunotoxicity, such as chemokine ligand (CXCL) 10, CXCL8, collagen type II alpha (COL3A), interleukin-1 alpha (IL-1α), plasminogen activator (PLA), plasminogen activator urokinase (PLAUR), vascular cell adhesion molecule (VCAM1), and the TNF receptor subfamily gene CD40 (CD40) (U.S. EPA, 2016). Among these genes, VCAM1 and PLAUR have been reported to induce chronic inflammation and vascularization in vivo . In this study, we included CXCL10, CXCL8, IL-1α, CD4, PLAUR, and VCAM1 ToxCast in vitro assays in the category of immunotoxicity dose-response analysis.
• Endocrine disruption: Estrogen and its related receptors have been associated with sexual development and reproductive function and cancer (Makela et al., 1994) . Four different estrogen receptor assays, all of which were related to estrogen receptor α (ESR α), were included in our study. In addition, the thyroid hormone receptor α was also included in the category of endocrine disruption dose-response analysis.
• Cellular response: Several in vitro studies have shown that PFOS exposure can cause multiple cellular responses, including inhibition of DNA synthesis, deficits in cell growth and oxidative stress (Hu and Hu, 2009; Slotkin et al., 2008) . These in vitro effects might help elucidate the toxic mechanisms of PFOS (Chen et al., 2014; Zeng et al., 2019) . Thus, the cellular responses detected in ToxCast program, including cytotoxicity, oxidative stress, DNA binding and cell cycle effects were included in the dose-response analyses.
Bayesian hierarchical model
In this study, we proposed a three-stage Bayesian hierarchical model for the dose-response analysis (Fig. S1) . In the first level (i.e., the experiment level), our model accounted for the variability within experiment. The variable was denoted as measured response in the study j at the dose level i and was assumed to be distributed normally around the predicted value µ .
~ ( , ) S1
The measured response was modeled as a linear function of the dose: = µ + , where µ is the mean response predicted by the dose-response model , and is the random residual which is represented as half-normal distribution ~(0, 2 ). In the second level (i.e., the study level), we modeled the variability between studies in the hierarchical model as below:
where the informative parameter "a" was assigned a log-normal prior distribution to ensure positive values and a realistic skewness. Note that µ was assumed to be a geometric mean.
Regarding the non-informative parameters b and c, uniform distribution with the lower bound ( or ) and upper bound ( or ) was assigned to these parameters. The lower bound and upper bound of the non-informative parameters were determined based on the biological consideration and prior information (the prior settings will be discussed in the next section). In the third stage (i.e., the population level), the population distribution with mean and standard deviation was described as follows:
We used normal distribution for the location hyperparameters (i.e., ) and half-Cauchy distribution for scale hyperparameters (i.e., ). We put a wide variance on (i.e., 1) to reflect the vague priors, while the was set a wide variance (i.e., 10) to reflect the weakly informative priors. The prior settings will be discussed in the next section.
Settings of priors for model parameters
The prior distribution is one of the critical elements in Bayesian interference. In the present study, Where Max (Res) and Min (Res) are the maximum and minimum response values in the input datasets. And DoseMax and DoseMin are the dose levels corresponding to the maximum and minimum responses, respectively. Based on the prior information from the previous study (Shao and Shapiro, 2018) , the parameter b was defined as a slope-equivalent parameter and determined by the dose-response trend and the overall slope in the input data, which was constrained from 0 to ( Max(Res)−Min (Res) Dose Max − Dose Min × 5). On the other hand, the parameter g was constrained from 0 to 15.
For the constrained parameters of log-formed Hill model, s a = log (DoseMax) S10 b lower = 0, b upper = 1.2 × Max(Res) S11 c lower = 0.3, c upper = 8 S12
In the log-formed Hill model, the parameter b was constrained from 0 to 1.2 multiplied by the maximum response, while the parameter c was constrained from 0.3 to 8 (Watt and Judson 2018) .
Estimation of posterior parameters
Convergence diagnosis
Four Markov chains of 10,000 iterations each, for the human, animal and ToxCast in vitro doseresponse model, respectively, were run with the first 5,000 iterations as "burn-in" iterations and the last 5,000 iterations were used as output iterations to check convergences. Corrected Scale Reduction Factors (̂) were calculated for the four chains to diagnose the convergences of Markov chains based on the method of Brooks and Gelman (Brooks and Gelman, 1998) . The ̂ values of population mean (µ ) and standard deviation ( ) for informative parameter "a" in the human, animal and ToxCast in vitro dose-response models were ≤1.05 for all simulations.
Markov chains trace plots
The Markov chains trace plots and its probability density function plots for population mean (µ ) and standard deviation ( ) of the informative parameter "a" are shown in Figs. S2-S3 , which provide a visualization of the Markov chains' convergences. Specifically, a trace plot for the four chains plots the observed chain value (y-axis) against the corresponding iteration number (x-axis).
The density plot for the four chains plots the observed chain value (x-axis) against density (y-axis).
The well-mixed trace plots showed that the parameters reached the steady state. The trace plots of parameters b and c also reached the steady state (data not shown).
Estimation of human population exceedance risk
Estimation of population-based dose response analysis
At the individual level, the model predicts posterior distribution of parameters a, b, and c for each individual, which can be used to estimate the uncertainty for each individual's dose-response curves (Fig. 2) . In the Bayesian hierarchical model (Fig. S1) , population dose-response curves can be made using the estimated values of population-level parameters. In this case, the model predicts a posterior distribution for the population parameters and , from which a virtual population of a can be generated via Monte Carlo sampling. Because the posterior distribution of and are also sampled, two-dimensional Monte Carlo (MC) was conducted (via MCMC) to separately evaluate the variability and uncertainty in the population. First-dimension MC is to randomly sample population i = 1….5,000 from the posterior distribution of and , resulting in the distribution across i which represents the uncertainty of population mean and standard deviation.
Second-dimension MC is to draw j = 1….5,000 individual pairs of , ~ (log( , ) , , )
based on a given set , and , and non-informative parameters , , . The pair of each i, j indicates an individual j (variability) drawing from the population i (uncertainty). Based on the population-level parameters, the population-level dose-response curves were reconstructed based on endpoints of serum cholesterol, PPAR activation, neurotoxicity, immunotoxicity, endocrine disruptors and cellular response, respectively.
Human biomonitoring data of the general population
To characterize the human population exceedance risk, we collected the human biomonitoring data for PFOS serum concentrations in the general population from different areas of the world and summarized in Table S2 . Theses PFOS concentrations from different countries and areas were assumed lognormal distribution with the reported concentration range and treated as the probability of D in the Equation 7 to estimate the population-based risk: exceedance probability (EP). In Table S2 , the observed serum PFOS concentrations range from 0.05 to 214, 3.5 to 29.6, 0.06 to 92.5, 0.4 to 1,656 ng/mL for the Asian, Australian, European, and North American populations, respectively. Median concentrations for PFOS from the North American populations appear to be higher than the European, Asian, and Australian populations (Table S2) .
Comparison of point of departure (POD)
To better understand the results from the present Bayesian dose-response modeling, we compared the derived EC10 values from this study with the outputs from the U.S. EPA's Benchmark Dose software (BMDS) and the recently published Bayesian Benchmark Dose interface (BBMD) developed by Shao and Shapiro (2018) . The BMDS and BBMD systems were used to fit the same datasets to estimate BMD doses using the default settings. To compare the EC10 values derived from this study versus the BMDS and BBMD methods, the benchmark response (BMR) was set as 10% (BMR = 0.1) in all analyses. In order to select the best-estimated BMD in the BMDS, the results of the Hill model was selected first, and then the one with the lowest Akaike information criterion (AIC) value was chosen if the Hill model failed to fit the data. For the BBMD method, the results were selected from the model-averaged BMD based on seven different dose-response models (e.g., Linear, Power, Hill and exponential model, etc.). All the results of POD estimation from different methods across the 34 selected datasets are summarized in Table S4 . The range of PODs for human studies was estimated to be 0.19-7.13, 0.27-5.96 and 6.13-19.8 ng/mL from this study, BMDS and BBMD, respectively. For animal studies, the range of PODs was estimated to 0.13-2.70 (this study), 0.11-2.14 (BMDS), and 0.31-2.57 (BBMD) mg/kg/day. In the ToxCast in vitro studies, the value ranged from 3.81 to 109, 0.96 to 94.23, and 0.69 to 69 µM based on the estimation of this study, BMDS and BBMD, respectively. The results showed that the PODs estimated from this study were similar to the outputs from BMDS and BBMD.
Note: the PBPK model simulated scenarios were daily oral exposure to PFOS at 1 mg/kg/day for 1 year in mice, rats, and monkeys, and for 50 years in humans. Footnote: population mean ( ) and standard deviation ( ) of the parameter a reflect the variability of EC50 in the Hill dose-response model in different datasets. The unit of and is ng/mL in humans, mg/kg/day in animal studies, and μM in ToxCast in vitro studies. The parameter b with the unit of percentage (% of control change) represents the Emax in the model, and c represents the Hill coefficient (unitless).
Supplementary Tables
Table S4
Comparison of the derived EC10 values from this study with the outputs from BMD and BBMD in the human, animal in vivo, and ToxCast in vitro studies
Reference or ToxCast assay
This study (at EC = 0.1) BMD a (at BMR = 0.1) BBMD b (at BMR = 0.1) Fig. S1 Bayesian hierarchical model for the dose-response analysis (modified from Chiu et al., (2014) The differences between the measured responses and predictions were assumed to have a distribution with variance , which was assigned a prior distribution (Pr). The dose-response model used informative parameter and non-informative parameters and . Informative parameter values were drawn from a population distribution with mean and variance , each of which was in turn assigned as prior distributions. Non-informative parameters were assigned the uniform distribution with lowerbound and upper-bound constrained values. • Datasets.zip file: All datasets used in the dose-response model development are included in this zip file. Please refer to Table 1 and Table 2 for details about these datasets.
Supplementary Figures
• ResultsCode.zip file: This zip file contains the R codes used to generate all results presented in the manuscript. Table 4. -Code for Fig_S2_S3: The R code used to generate results in Fig. S2 and Fig. S3 .
-Code for Table_3: The R code used to generate results in Table 3 .
"StanResults" folder:
-Data.rds: The "rds" file stores all the observed data from selected human, animal and ToxCast in vitro studies. -PBPK_.rds: These "rds" files contain the PBPK-mrgsolve code for mice (PBPK_Mice.rds), rats (PBPK_Rat.rds), monkeys (PBPK_Monkey.rds), and humans (PBPK_Human.rds).
• BMDS_BBMD_Analysis.zip file: This zip file contains the BBMD report, BMD report and input datasets. • Set your working directory: Set your working directory as the folder "Datasets".
Instructions on the model code
• Run the Stan code: Run all the code in the "STANCode" R file to compile the dose-response model.
• Run the R code: Run the code in the "RScript" R file step by step as described below:
• Lines 1-5: Loading the required R packages • Lines 7-11: Set up the Rstan model setting • Lines 13 -178: Read the datasets from external files and create a parameter list for each endpoint for use in the STAN model. The PlotCode folder stores all R codes for reproducing results presented in the figures and tables in the present manuscript. The "StanResults" folder stores the results after running the Bayesian dose-response model using STAN as different ".rds" files. Please refer to the Section 8.1 above for a detailed explanation of each ".rds" file.
• Set the working directory as the folder "StanResults" before running each figure or table code file.
• Open one of the R codes under the folder "PlotCode" and run it to reproduce the results presented in the corresponding figure and/or table in the manuscript.
